MHMengke Huang

Mengke Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Mengke Huang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Lu Hui

    Department of Clinical Laboratory, Honghui Hospital, Xi’an Jiaotong University, Xi’an, China

    1 shared publication
  • Ting Liu

    Department of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Xiaolin Chen

    Department of Laboratory Medicine West China Second University Hospital, Sichuan University Chengdu China

    1 shared publication
  • Yong-Mei Jiang

    Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    TANK-Binding Kinase 1 in the Pathogenesis and Treatment of Inflammation-Related Diseases

    by Lu Hui, Xiaolin Chen, Mengke Huang, Yongmei Jiang, Ting Liu

    TANK-binding kinase 1 (TBK1) is a key signaling kinase involved in innate immune and inflammatory responses. TBK1 drives immune cells to participate in the inflammatory response by activating the NF-κB and interferon regulatory factor signaling pathways in immune cells, promoting the expression of pro-inflammatory genes, and regulating immune cell function. Thus, it plays a crucial role in initiating a signaling cascade that establishes an inflammatory environment. In inflammation-related diseases, TBK1 acts as a bridge linking inflammation to immunity, metabolism, or tumorigenesis, playing an important role in the pathogenesis of immune-mediated inflammatory diseases, metabolic, inflammatory syndromes, and inflammation-associated cancers by regulating the activation of inflammatory pathways and the production of inflammatory cytokines in cells. In this review, we focused on the mechanisms of TBK1 in immune cells and inflammatory-related diseases, providing new insights for further studies targeting TBK1 as a potential treatment for inflammation-related diseases. Thus, optimizing and investigating highly selective cell-specific TBK1 inhibitors is important for their application in these diseases.